Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Lactobacillus casei alleviated the abnormal increase of cholestasis-related liver indices during tuberculosis treatment: a post hoc analysis of randomized controlled trial.

  • 2021-07-19
  • Molecular Nutrition & Food Research 65(16)
    • Ke Xiong
    • Jing Cai
    • Peiying Liu
    • Jinyu Wang
    • Shanliang Zhao
    • Lei Xu
    • Yang Yang
    • Jiahong Liu
    • A. Ma

Abstract

Scope: Probiotics are promising in mitigating drug-induced liver injury in animal experiments. However, the clinical evidence is absent. The objective is to investigate the effect of adjunctive Lactobacillus casei on tuberculosis-drug-induced liver injury.

Methods and results: A post hoc analysis is conducted for a previous randomized controlled trial. The trial is registered at the Chinese Clinical Trial Registry (No. ChiCTR-IOR-17013210). Four hundred twenty nine patients are allocated to receive standard tuberculosis therapy alone (control group), or together with 1 × 1010 colony-forming units (CFU) per day (low-dose group), or 2 × 1010 CFU per day of L. casei (high-dose group) during tuberculosis treatment. The L. casei supplementation significantly reduced the incidence of the abnormal increase of cholestasis-related liver indices including alkaline phosphatase (p = 0.024) and bilirubin (p = 0.013). Plasma lipopolysaccharide (p = 0.02), intestinal permeability biomarkers including zonula occludens-1 (p = 0.001) and intestinal fatty acid binding protein (p = 0.002) are significantly reduced. The gut microbiota composition is dramatically altered with a reduction of Bacteroidetes (p < 0.001) and a corresponding increase of Actinobacteria (p < 0.001) and Firmicutes (p = 0.003).

Conclusions: L. casei supplementation is beneficial for suppressing abnormally elevated cholestasis-related liver indices during tuberculosis treatment, which may be related to its modification on blood lipopolysaccharide, intestinal barrier function, and gut microbiota.

Keywords: drug-induced liver injury; gut microbiota; intestinal barrier function; probiotics; randomized controlled trial; tuberculosis.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lacticaseibacillus caseiAltered Gut Microbiota CompositionBeneficial
Moderate
Lacticaseibacillus caseiImproved Intestinal Barrier FunctionBeneficial
Moderate
Lacticaseibacillus caseiReduced Abnormally Elevated Cholestasis-Related Liver IndicesBeneficial
Moderate
Lacticaseibacillus caseiReduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lacticaseibacillus casei R0215Altered Gut Microbiota CompositionBeneficial
Moderate
Lacticaseibacillus casei R0215Improved Gut PermeabilityBeneficial
Large
Lacticaseibacillus casei R0215Reduced Incidence of CholestasisBeneficial
Moderate
Lacticaseibacillus casei R0215Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus caseiAltered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus caseiImproved Gut PermeabilityBeneficial
Large
Lactobacillus caseiReduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei HA-108Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei HA-108Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei HA-108Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei PXN 37Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei PXN 37Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei PXN 37Reduced Alkaline Phosphatase LevelsBeneficial
Moderate
Lactobacillus casei PXN 37Reduced Incidence of HyperbilirubinemiaBeneficial
Moderate
Lactobacillus casei PXN 37Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei R0215Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei R0215Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei R0215Reduced Abnormally Elevated Cholestasis-Related Liver IndicesBeneficial
Moderate
Lactobacillus casei R0215Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei SD-5213Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei SD-5213Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Incidence of CholestasisBeneficial
Moderate
Lactobacillus casei SD-5213Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei SD-5842Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei SD-5842Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei SD-5842Reduced Incidence of CholestasisBeneficial
Moderate
Lactobacillus casei SD-5842Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei subsp. caseiImproved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei subsp. caseiIncreased Gut Microbiota DiversityBeneficial
Large
Lactobacillus casei subsp. caseiReduced Abnormal Cholestasis-Related Liver IndicesBeneficial
Moderate
Lactobacillus casei subsp. caseiReduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei UALc-03Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei UALc-03Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei UALc-03Reduced Incidence of CholestasisBeneficial
Moderate
Lactobacillus casei UALc-03Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
Lactobacillus casei VK4Altered Gut Microbiota CompositionBeneficial
Moderate
Lactobacillus casei VK4Improved Intestinal Barrier FunctionBeneficial
Moderate
Lactobacillus casei VK4Reduced Abnormal Cholestasis-Related Liver IndicesBeneficial
Moderate
Lactobacillus casei VK4Reduced Plasma Lipopolysaccharide LevelsBeneficial
Moderate
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.